Hyloris Adds Aguettant Deals For Maxigesic IV In Europe
Partner AFT Signs Licensing Agreements In Eight European Markets
Hyloris has secured licensing deals with Aguettant for its Maxigesic IV combination of paracetamol and ibuprofen in a further eight European markets through partner AFT Pharmaceuticals.
You may also be interested in...
After partnering with companies like Purna Female Healthcare and AFT Pharmaceuticals, Belgian value-added medicines specialist Hyloris has announced plans to add three new products to its pipeline in the coming months with a goal of having 14 commercial products by 2024.
Plus deals involving AbbVie/Mitokinin, Roivant/Silicon Therapeutics, CASI/Cleave Therapeutics, Tallac/ALX Oncology, AgeX/LyGenesis, Chinook/Evotec and more.
Stada has appointed a new specialty head who will have global responsibility for the firm’s biosimilars business. Meanwhile, Hyloris has named a new business development chief and a generics industry veteran has joined Slayback’s board.